

ESTTA Tracking number: **ESTTA437574**

Filing date: **10/25/2011**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Proceeding	91184464
Party	Plaintiff Medimmune, Inc.
Correspondence Address	CONSTANCE GOLDEN ABELMAN FRAYNE & SCHWAB 666 THIRD AVENUE NEW YORK, NY 10017 UNITED STATES cgolden@lawabel.com, Rdahl@lawabel.com
Submission	Stipulated/Consent Motion to Extend
Filer's Name	Constance Golden
Filer's e-mail	cgolden@lawabel.com
Signature	/Constance Golden/
Date	10/25/2011
Attachments	20111025105032206.pdf ( 3 pages )(103092 bytes )

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

In Re Application No. 79/043095 Published March 18, 2008  
In Re Application No. 79/039076 Published February 5, 2008

Medimmune, Inc.

Opposer

v.

Sygnis Pharma AG

Applicant

Opposition No. 91184464

Opposition No. 91184465

CONSOLIDATED

**CONSENTED REQUEST FOR SUSPENSION**

Pursuant to 37 CFR §2.117(c) of the Trademark Rules of Practice and §510.03(a) of the Trademark Trial and Appeal Board Manual of Procedure, Applicant, with the consent of the Opposer, requests a further 90 day suspension of the proceeding to allow the parties to finalize their settlement efforts.

The parties have been working diligently towards finalizing settlement and resolving the pending Oppositions. The parties respectfully inform the Board that they have been actively engaged in settlement discussions for quite some time and have agreed on August 18, 2011 to a proposed settlement in principle of the issues between the parties. The agreed to issues include:

1. SYGNIS only used for a company name and not a product name (except as the corporate name might incidentally appear on packaging, etc.)
2. Consistently use SYGNIS in combination with "Pharma AG" (at least in the first and most prominent use; preference to have the wording added to the logo if possible).

3. A field of use restriction consistent with an agreement with Abbott Laboratories.
4. Withdraw (and do not re-file) the U.S. trademark application for SYGNIS.

In order to finalize the terms of a Settlement Agreement and to preserve their rights to proceed in this matter, the parties request a further extension of the suspension period while the terms of their written settlement agreement are finalized. The parties remain hopeful that a final settlement will be reached within the next ninety days.

It is requested that the Board grant this request and approve the scheduling order set forth below:

Expert Disclosures Due:	January 27, 2012
Discovery Closes:	February 26, 2012
Plaintiff's Pretrial Disclosures:	April 11, 2012
Plaintiff's 30-day Trial Period Ends:	May 26, 2012
Defendant's Pretrial Disclosures:	June 10, 2012
Defendant's 30-day Trial period Ends:	July 25, 2012
Plaintiff's Rebuttal Disclosures:	August 9, 2012
Plaintiff's 15-day Rebuttal Period Ends:	September 8, 2012

On October 24, 2011 counsel for both parties consented and agreed via telephone and email to this motion and further suspension of this proceeding.

Wherefore, it is requested that this suspension be granted.

Respectfully submitted,

  
\_\_\_\_\_  
CONSTANCE GOLDEN

ABELMAN FRAYNE & SCHWAB  
666 Third Avenue  
New York, NY 10017  
212-949-9022

## CERTIFICATE OF SERVICE

I hereby certify that a true copy of the foregoing was served by first class mail, postage prepaid this 25<sup>th</sup> day of October, 2011 on the following:

Catherine J. Holland, Esq.  
KNOBBE, MARTENS, OLSON & BEAR, LLP  
2040 Main Street, Fourteenth Floor  
Irvine, California 92615

A handwritten signature in cursive script, reading "Constance Golden", written in black ink.

---

CONSTANCE GOLDEN